|
|
 |
 Matt
Zuga
David
C. U'Prichard, PhD
Jigar
Raythatha
Frank
A. Bonsal, Jr.
Philip
Goelet, PhD
Scientific
Council
CEO's
Council
|
|
Philip Goelet, PhD, Advisor
Dr. Goelet is a founding member of Red Abbey Venture
Partners. Dr. Goelet formed his relationship with Mr. Bonsal in 1990 when
he joined the Board of Directors of Molecular Tool, Inc., a Baltimore,
MD based life sciences company that was founded by Dr. Goelet. In 1997,
Mr. Bonsal and Dr. Goelet launched their personal life sciences investment
program, as described in “Historical Investment Activity and Performance.”
Dr. Goelet is a scientist, entrepreneur and investor, with research experience
in molecular biology and management experience in the biotechnology and
asset management industries. Dr. Goelet was educated at Oxford University
and received an MPhil and PhD in biochemistry from the University of Cambridge,
where he studied under Drs. Jonathan Karn and Sydney Brenner at the Laboratory
of Molecular Biology. From 1984 to 1987, Dr. Goelet worked as a Helen
Hay Whitney Fellow at Columbia University in the laboratory of Dr. Eric
Kandel. Dr. Goelet has published several scientific articles and holds
patents in the fields of nucleic acid chemistry, virology, neurobiology,
genomics and drug discovery.
Dr. Goelet is the co-founder of Acidophil, LLC, an intellectual property
holding company that oversees the development of technologies invented
by Dr. Goelet, Dr. Brenner and a group of scientific associates. Dr. Goelet
served as an officer and director of the Rhode Island Corporation (a private
investment company) and its successor, NORIC, from 1995 until its acquisition
by Pogo Producing Company (NASDAQ: PPP) in 2001. Dr. Goelet was a co-founder
of Ribotargets Holdings Plc. (an RNA structure-based drug discovery company)
and served on its Board of Directors from 1997 to 2000.
In 1990, Dr. Goelet co-founded Molecular Tool, Inc., where he co-invented
SNP (“single nucleotide polymorphism”) analysis technology.
As Chairman and CEO, Dr. Goelet completed Molecular Tool’s merger
with GeneScreen, Inc. As a member of the Board of Directors of GeneScreen,
Inc., he participated in its acquisition by Orchid Biosciences, Inc. (NASDAQ:
ORCH), where he served on the Scientific Advisory Board.
Dr. Goelet is a board member of the Boyce Thompson Institute of Plant
Research, Ithaca, NY, and a member of the Senior Advisory Group for The
Johns Hopkins Medicine Alliance for Science and Technology Development.
*****
Contact Philip: pgoelet@redabbey.com
|
|
 |
|
